HIV and hepatitis C coinfection within the CAESAR study

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 174-179

  Amin, J ^a   Kaye, M ^b   Skidmore, S ^b   Pillay, D ^b   Cooper, D A ^a   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Hepatitis C; Hepatotoxicity; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; HEPATITIS C ANTIBODY; LAMIVUDINE; LOVIRIDE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; CANADA; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; ETHNOLOGY; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MALE; MULTICENTER STUDY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEXUAL TRANSMISSION; SOUTH AFRICA; VIRUS TRANSMISSION;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CANADA; DISEASE PROGRESSION; EUROPE; HEPATITIS C; HEPATITIS C ANTIBODIES; HOMOSEXUALITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; SOUTH AFRICA;

EID: 2942632930     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00207.x     Document Type: Article

References (32)

1. Telfer PT, Brown D, Devereux H, Lee CA, DuSheiko GM. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994; 88: 397-399.
2. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Br Med J 1997; 315: 333-337.
3. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-561.
4. Pol S, Lamorthe B, Thi NT et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28: 945-950.
5. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
6. Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-953.
7. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. JAcquir Immune Defic Syndr 1993; 6: 602-610.
8. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
9. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995; 172: 1503-1508.
10. Piroth L, Duong M, Quantin C et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12: 381-388.
11. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
12. Furrer H, Fux C. Opportunistic infections: an update. J HIV Ther 2002; 7: 2-7.
13. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1-4.
14. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
15. El Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003; 98: 167-174.
16. CAESAR Co-ordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
17. Puren AJ. The HIV-1 epidemic in South Africa. Oral Dis 2002; 8 (Suppl. 2): 27-31.
18. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993; 17: 117-119.
19. Brau N, Bini EJ, Shahidi A et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002; 97: 2071-2078.
20. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev 1996; 18: 137-148.
21. Kaldor JM, Archer GT, Buring ML et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust 1992; 157: 227-230.
22. Danta M, Brown M, Jacobs M, Dusheiko G, Bhagani S. Epidemiology of acute HCV infection in a London cohort of HIV positive homosexual men. Hepatology 2003; 38 (Suppl. 1): 431A.
23. Filippini P, Coppola N, Scolastico C et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Trans Dis 2001; 28: 725-729.
24. Marcellin P, Martinot-Peignoux M, Elias A et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994; 170: 433-435.
25. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34: 1259-1263.
26. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-48.
27. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000; 31: 1234-1239.
28. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283: 74-80.
29. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
30. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-2902.
31. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. J Am Med Assoc 2002; 288: 199-206.
32. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003; 7: 179-194.